Bristol-Myers UPSA Group sales rise 4% to $140 mil. in second quarter.
This article was originally published in The Tan Sheet
Executive Summary
BRISTOL-MYERS UPSA GROUP SALES RISE 4% TO $140 MIL. in the second quarter, with sales for the French group's Efferalgan effervescent acetaminophen product up 13% to $36 mil., excluding foreign exchange rates. The majority of the UPSA business derives from analgesic sales in Europe. Bufferin worldwide sales increased 5% during the quarter to $35 mil., excluding foreign exchange. Aided by the growth in analgesics, Bristol's international consumer medicines sales grew 4% for the period.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: